世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

がん治療用チェックポイント阻害薬市場レポート 2017-2027年

Checkpoint Inhibitors for Treating Cancer Market Report 2017-2027

Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs

 

出版社 出版年月価格 ページ数図表数
Visiongain
ヴィジョンゲイン社
2017年10月お問い合わせください 139 96

サマリー

Report Details

Where is the Checkpoint Inhibitors for Treating Cancer market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead
Our 139-page report provides 96 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Checkpoint Inhibitors for Treating Cancer market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are forecasts for 3 submarkets and 7 Drugs in the report at a global level, as well as profiles for 19 pipeline drug candidates

Global Checkpoint Inhibitors for Treating Cancer Market by Type
• PD-1 Inhibitors
• CLTA-4 Inhibitors
• Pipeline Drugs

Global Checkpoint Inhibitors for Treating Cancer Market by Drug
• Opdivo (nivolumab)
• Keytruda (pembrolizumab)
• Yervoy (ipilimumab)
• Tecentriq (Atezolizumab)
• Imfinizi (Durvalumab)
• Bavencio - Avelumab - (MSB0010718C)
• Tremelimumab (CP-675,206)

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 8 major regional/national markets:
• The US
• Japan
• Germany
• The UK
• Italy
• France
• Spain
• Asia-Pacific

The report also includes profiles and for some of the leading companies in the Checkpoint Inhibitors for Treating Cancer market, with a focus on this segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, the US, the UK and the APAC region in particular, will continue to achieve high revenue growth to 2027.

Leading companies and the potential for market growth
Overall world revenue for Checkpoint Inhibitors for Treating Cancer will surpass $7.6bn in 2017, our work calculates. We predict strong revenue growth through to 2027.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Checkpoint Inhibitors for Treating Cancer Market report helps you
In summary, our 139-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the Checkpoint Inhibitors for Treating Cancer market, with forecasts for 3 submarkets and 7 Drugs, each forecasted at a global level – discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2027 for 8 key regional and national markets – See forecasts for the Checkpoint Inhibitors for Treating Cancer in Asia-Pacific, the US, Germany, France, the UK, Italy, France, and Japan,
• What stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market – including company profiles for some of the major companies involved in the Checkpoint Inhibitors for Treating Cancer market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly updated report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.

Visiongain’s study is for everybody needing commercial analyses for the Checkpoint Inhibitors for Treating Cancer market and leading companies. You will find data, trends and predictions.

Get our report today Checkpoint Inhibitors for Treating Cancer Market Report 2017-2027: Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs.



目次

Table of Contents

1. Report Overview
1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to the Checkpoint Inhibitor Anti-Cancer World Market 2016
2.1 Checkpoint Inhibitors: A New Era in Immunotherapy
2.2 Checkpoint Inhibitor Drug Treatments in Oncology

3. Leading Checkpoint Inhibitors: Anti-Cancer Drug Forecasts 2017-2027 and Leading Companies in the World Market
3.1 Leading Checkpoint Inhibitor Anti-Cancer Drug Treatments on the Market in 2016
3.1.1 Yervoy (ipilimumab) – Bristol-Myers Squibb
3.1.1.1 Yervoy: Sales Analysis
3.1.2 Opdivo (nivolumab) – Bristol-Myers Squibb/Ono Pharmaceutical
3.1.2.1 Opdivo: Sales Analysis
3.1.3 Keytruda (pembrolizumab) – Merck & Co.
3.1.3.1 Keytruda: Sales Analysis
3.2 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Market in 2016
3.2.1 Bristol-Myers Squibb Leads the Market

4. Checkpoint Inhibitor Anti-Cancer Treatment: World Market 2017-2027
4.1 The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2016
4.2 The World Anti-Cancer Checkpoint Inhibitor Market: Revenue Forecasts 2017-2027
4.3 Leading Checkpoint Inhibitor Treatment Submarkets Forecast 2017-2027
4.3.1 The CTLA-4 Inhibitors Submarket Forecast 2017-2027
4.3.2 The PD-1 Inhibitors Submarket Forecast 2017-2027
4.3.3 Changing Market Shares: PD-1 Inhibitors Will Lead the Market
4.3.4 Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027
4.3.4.1 Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Market
4.3.4.2 Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market

5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027
5.1 Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatments Market 2017-2027
5.2 World Checkpoint Inhibitor Anti-Cancer Treatment Market: Regional Forecast 2017-2027
5.2.1 How Will Regional Market Shares Change to 2027?
5.3 The US Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.4 The EU Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.4.1 Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.4.2 France: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.4.3 Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.4.4 The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.4.5 Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.5 Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.6 The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027

6. The Checkpoint Inhibitor Anti-Cancer Treatment Market Pipeline Analysis 2017-2027
6.1 Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
6.1.1 Tecentriq (Atezolizumab)
6.1.2 Imfinizi (Durvalumab)
6.1.3 Bavencio - Avelumab - (MSB0010718C) – Merck KGaA/Pfizer
6.1.4 Pidilizumab (CT-011) – CureTech Ltd
6.1.5 AMP-224 – GSK/Amplimmune
6.1.6 TSR-042 – TESARO Bio/AnaptysBio
6.1.7 AMP-514 (MEDI0680) – AstraZeneca/MedImmune
6.1.8 REGN2810 – Regeneron/Sanofi
6.2 CTLA-4 Inhibitors
6.2.1 Tremelimumab (CP-675,206) - AstraZeneca
6.3 LAG-3 (lymphocyte activation gene-3) Inhibitors
6.3.1 IMP321- Prima Biomed
6.3.2 BMS-986016 - Bristol-Myers Squibb
6.3.3 IMP701 – Prima BioMed/Novartis
6.4 KIR Inhibitors
6.4.1 Lirilumab (IPH2102/BMS-986015) – Innate Pharma/Bristol-Myers Squibb
6.5 Anti-NKG2A Inhibitors
6.5.1 IPH2201 – Innate Pharma/AstraZeneca/MedImmune
6.6 Other Checkpoint Inhibitors
6.6.1 VISTA Inhibitors
6.6.1.1 CA-170 – Curis Inc/Aurigene Discovery Technologies
6.6.2 IDO and TDO Inhibitors
6.6.2.1 Indoximod (NLG-9189) – NewLink Genetics
6.6.2.2 NLG919 – NewLink Genetics
6.6.2.3 INCB024360 – Incyte/Roche
6.6.3 A2aR Inhibitors
6.6.3.1 HTL-1071 – AstraZeneca/Heptares
6.6.4 Future Areas of Pipeline Research

7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027
7.1 SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027
7.2 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Market
7.2.1 A Novel Treatment Method that Harnesses the Immune System’s Vast Potential
7.2.2 Pricing of the Treatments Will Attract Companies
7.2.3 Cost of Treatment Will Restrain Market Access
7.2.4 Side Effects May Prohibit Growth
7.3 Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Market
7.3.1 Biomarkers Pave the Way for Optimum Utility
7.3.2 Combination Therapies Are Achieving Superior Results
7.3.3 The Cost Burden of Expensive Drug Treatments on Healthcare Systems
7.3.4 Crowding of the Market with Similar Products

8. Conclusions
8.1 The Global Checkpoint Inhibitor Anti-Cancer Treatment Market: Current World Outlook
8.1.1 Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Market to 2027
8.2 Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027: The US and EU Will Retain Their Lead
8.3 The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Market

Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form

List of Figures
Figure 1.1 Global Checkpoint Inhibitor Anti-Cancer Treatment Market Segmentation Overview, 2016
Figure 3.1 Yervoy (ipilimumab): Historical Sales ($bn), 2013-2016
Figure 3.2 Yervoy Forecast, Revenue ($bn), 2016-2027
Figure 3.3 Opdivo Forecast, Revenue ($bn), 2016-2027
Figure 3.4 Keytruda Forecast, Revenue ($bn),2016-2027
Figure 3.5 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2016
Figure 3.6 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2017
Figure 4.1 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2016
Figure 4.2 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), 2016-2027
Figure 4.3 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2016
Figure 4.4 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), 2016-2027
Figure 4.5 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), 2016-2027
Figure 4.6 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2022
Figure 4.7 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2027
Figure 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Shares (%), 2016
Figure 5.2 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), 2016-2027
Figure 5.3 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2022
Figure 5.4 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2027
Figure 5.5 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.6 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.7 EU Market for the Checkpoint Inhibitor Cancer Treatment by Leading Country (%), 2016
Figure 5.8 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market, Market Sizes ($bn), 2016-2027
Figure 5.9 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.10 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2017-2027
Figure 5.11 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.12 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.13 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.14 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.15 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 6.1 Tecentriq Forecast: Revenue ($bn), 2016-2027
Figure 6.2 Imfinizi Forecast: Revenue ($bn), 2016-2027
Figure 6.3 Bavencio Forecast: Revenue ($bn), 2016-2027
Figure 6.4 Tremelimumab Forecast: Revenue ($bn), 2016-2027
Figure 8.1 Checkpoint Inhibitor Anti-Cancer Drug Treatment Market Forecast by Class: Market Sizes ($bn), 2016-2027
Figure 8.2 Checkpoint Inhibitor Anti-Cancer Treatment Market Forecasts by Region: Market Size ($bn), 2016, 2018, 2022, and 2027

List of Tables
Table 2.1 Main Types of Checkpoint Inhibitors in Development, 2016
Table 3.1 Yervoy (Ipilimumab): Historical Sales ($bn, AGR%), 2013-2016
Table 3.2 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 3.3 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 3.4 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 3.5 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 3.6 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 3.7 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%),2022-2027
Table 3.8 Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2016
Table 3.9 Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2017
Table 4.1 Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2016
Table 4.2 Checkpoint Inhibitors by Revenue ($bn), 2016
Table 4.3 Checkpoint Inhibitors by Revenue ($bn), 2017
Table 4.4 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2016-2022
Table 4.5 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2022-2027
Table 4.6 Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2016
Table 4.7 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2016-2022
Table 4.8 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2022-2027
Table 4.9 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2016-2022
Table 4.10 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2022-2027
Table 4.11 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2016-2022
Table 4.12 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2022-2027
Table 4.13 Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market,2017-2027
Table 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Sizes ($bn), Market Shares (%), 2016
Table 5.2 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%),2016-2022
Table 5.3 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2022-2027
Table 5.4 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2016-2022
Table 5.5 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2022-2027
Table 5.6 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 5.7 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.8 EU Market Shares (%), 2016-2022
Table 5.9 EU Market Shares (%), 2022-2027
Table 5.10 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2022
Table 5.11 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.12 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 5.13 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.14 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2022
Table 5.15 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.16 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2022
Table 5.17 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.18 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 5.19 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.20 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 5.21 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.22 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2022
Table 5.23 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.24 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2022
Table 5.25 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 6.1 Selected Combination Therapies for Atezolizumab, 2016
Table 6.2 Tecentriq Forecast: Revenue ($bn), 2017-2022
Table 6.3 TecentriqForecast: Revenue ($bn), 2022-2027
Table 6.4 Imfinizi Forecast: Revenue ($bn), 2017-2022
Table 6.5 Imfinizi Forecast: Revenue ($bn), 2022-2027
Table 6.6 Bavencio Forecast: Revenue ($bn), 2016-2022
Table 6.7 Bavencio Forecast: Revenue ($bn), 2022-2027
Table 6.8 Tremelimumab Forecast: Revenue ($bn), 2016-2027
Table 6.9 Tremelimumab Forecast: Revenue ($bn), 2022-2027
Table 7.1 Strengths and Weaknesses of the Checkpoint Inhibitor Cancer Treatment Market, 2016
Table 7.2 Opportunities and Threats of the Checkpoint Inhibitor Cancer Treatment Market, 2015
Table 8.1 Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2016, 2018, 2022, and 2027
Table 8.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2016, 2018, 2022, and 2027

 

Companies Listed

AbbVie
Agilent Technologies
Amgen
Amplimmune
AnaptysBio
AstraZeneca
Aurigene Discovery Technologies
Bristol-Myers Squibb
Celgene
CoStim Pharmaceuticals
CureTech Ltd
Curis Inc
Daiichi Sankyo
Dako (subsidiary of Agilent Technologies)
DMC (Data Monitoring Committee)
DNAtrix
Dynavax
Eddingpharm
GlaxoSmithKline (GSK)
Heptares
Immutep
Incyte
Innate Pharma
INSERM
iTeos Therapeutics
J&J
Medarex
MedImmune
Medivation Inc
Merck & Co.
Merck KGaA
Mirati Therapeutics
NEC Corporation
NewLink Genetics
Novartis
Novo Nordisk
Ono Pharmaceutical
Pfizer
Pharmacyclics
Plexxikon (subsidiary of Daiichi Sankyo)
Prima Biomed
Regeneron
Roche
Sanofi
Sosei Group Corporation
Syndax
TESARO Inc
Teva Pharmaceutical Industries

List of Organizations
American Cancer Society
ASCO (American Society of Clinical Oncology)
CHMP (Committee for Medicinal Products for Human Use)
Commission de la Transparence
CRI (Cancer Research Institute)
EMA (European Medicines Agency)
European Organisation for Research and Treatment and Cancer (EORTC)
FDA (US Food and Drug Administration)
French National Authority for Health
IGR (Institut Gustav Roussy)
LICR (Ludwig Cancer Research)
MHLW (Ministry of Health, Labour, and Welfare)
MHRA (Medicines and Healthcare Products Regulatory Agency)
NHS (National Health Service)
NICE (the National Institute for Health and Care Excellence)
Paris University
QIMR Berghofer Medical Research Institute
The de Duve Institute
WHO (World Health Organization)
Yamaguchi University

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る